Is Certara Stock a Good Investment in Biosimulation?

The Nanalyze Disruptive Tech Stock Catalog boasts more than 450 companies. This thing is a beast, and the more we feed it, the bigger it gets. Our goal is to make it more lean and mean – trim the fat, so to speak – so it’s more easily digestible. However, when the folks who help us pay the bills suggest a stock that they like, we dig in. It also whets our appetite if that company is a competitor to one of the stocks in our Nanalyze Disruptive Tech Portfolio. And it definitely doesn’t hurt if said stock is a pure play in one of our core investment themes. 

Certara stock (CERT) appears to check all the boxes. Nominated by one of our lovely subscribers, the New Jerzee-based company serves the drug development industry by offering software and services around its biosimulation platform. It claims to compete indirectly with companies like Schrödinger (SDGR), which uses a computational physics-based platform and machine learning to accelerate drug discovery. In addition, biosimulation involves creating a digital twin of a biological system to predict how drugs behave in different people. We believe the digitization of real-world processes into virtual platforms for monitoring systems and predicting outcomes is a key disruptive technology.

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.